InvestorsHub Logo
Followers 46
Posts 6251
Boards Moderated 0
Alias Born 06/17/2009

Re: XenaLives post# 107836

Friday, 06/09/2017 6:27:21 PM

Friday, June 09, 2017 6:27:21 PM

Post# of 462177
Xena, it becomes a whole new ballgame if Biogen wants to use 2-73 on patients in a P2 trial. I doubt the MTA with Biogen covers that aspect as the limitation of Biogen's work was in the lab, per the PR.

With your thoughts in mind, BIO 2017 has become more interesting to me.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News